Advertisement
Advertisement
RAPP
Rapport Therapeutics, Inc. Common Stock
41.90
USDSponsored
+0.96
+2.33%
Jul 30, 12:42 UTC -4
Open
RAPP Earnings Reports
Positive Surprise Ratio
RAPP beat 6 of 8 last estimates.
75%
Next Report
Next Week
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.98
Implied change from Q1 26 (Revenue/ EPS)
-100.00%
/+133.33%
Implied change from Q2 25 (Revenue/ EPS)
--
/+30.67%
Rapport Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, RAPP reported earnings of -0.42 USD per share (EPS) for Q1 26, beating the estimate of -0.68 USD, resulting in a 38.61% surprise. Revenue reached 20.00 million, compared to an expected 8.74 million, with a 128.76% difference. The market reacted with a +7.74% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.98 USD, with revenue projected to reach -- USD, implying an increase of 133.33% EPS, and decrease of -100.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Viking Therapeutics, Inc
Report Date
Jul 29, 2026 For Q2 26
Estimate
-$1.27
Actual
-$1.10
Surprise
+13.52%
Bristol-Myers Squibb Co.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.60
Actual
$2.04
Surprise
+27.37%
Regeneron Pharmaceuticals Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$10.52
Actual
$14.29
Surprise
+35.73%
Alnylam Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.58
Actual
$1.84
Surprise
+16.03%
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.31
Actual
-$0.34
Surprise
-8.94%
uniQure N.V.
Report Date
Jul 29, 2026 For Q2 26
Estimate
-$0.84
Actual
-$1.22
Surprise
-45.12%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
$0.00
Surprise
+100.00%
Fortrea Holdings Inc. Common Stock
Report Date
Jul 29, 2026 For Q2 26
Estimate
$0.18
Actual
$0.23
Surprise
+24.93%
FAQ
What were Rapport Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Rapport Therapeutics, Inc. Common Stock reported EPS of -$0.42, beating estimates by 38.61%, and revenue of $20.00M, 128.76% above expectations.
How did the market react to Rapport Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 7.74%, changed from $37.06 before the earnings release to $39.93 the day after.
When is Rapport Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for Rapport Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, Rapport Therapeutics, Inc. Common Stock is expected to report EPS of -$0.98 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement